The AGILE Clinical Trial Platform
Faster drug testing for COVID-19, for a faster return to normal life
The AGILE clinical trial platform is a new type of study designed for pandemic drug testing which represents a world-first for infectious diseases – capable of testing multiple potential treatments in parallel and speeding up testing by pooling control data across patient groups
The coronavirus pandemic is like nothing we’ve seen in modern times. Its transmissibility and severity have overwhelmed conventional means of managing infectious diseases, and so far quarantine – with its considerable social and economic costs – is our only effective defence.
The AGILE clinical trial platform has been launched specifically to test new COVID-19 treatments, faster than ever before. It bridges the gap between non-human trials and large-scale testing, so potential new treatments can go through the important testing stages in a matter of months rather than years, while maintaining a high level of safety at all times.
This provides the potential for one or more suitable treatment options to become broadly available for patients with COVID-19 much sooner, and ultimately, allowing us to restart society.
The MHRA (Medicines and Healthcare products Regulatory Agency) has fully evaluated this platform and given its approval. The UK regulatory body has adapted rapidly to the altered circumstances in the pandemic to help efforts against coronavirus.
Navigating the site
More information about the trial and how to take part can be found in the FOR PATIENTS area of the site.
All study documents can be downloaded from the FOR SITE STAFF area of the site. Please note that documents are password protected and can only be accessed by authorised staff.
The AGILE Initiative is made possible thanks to support provided through a variety of donors. In addition to funding provided by Unitaid and the Steve Morgan Foundation, some candidate-specific trials will be funded directly and solely through independent private companies (for example, Ridgeback Biotherapeutics). Collaborative financial support has also been provided by the Liverpool School of Tropical Medicine, University of Liverpool, and Southampton Clinical Trials Unit as well as the NHS (Liverpool University Hospitals NHS Foundation Trust).